ABCB1 C1236T, G2677T/A and C3435T polymorphisms in systemic lupus erythematosus patients

Brazilian Journal of Medical and Biological Research

Volumn 41, Issue 9, 2008, Pages 769-772

  Gonzalez, T P ^a   Mucenic, T ^b   Brenol, J C T ^b   Xavier, R M ^b   Schiengold, M ^a   Chies, J A B ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

ABCB1; MDR1; P glycoprotein; Polymorphism; Systemic lupus erythematosus

Indexed keywords

DNA FRAGMENT; GENOMIC DNA; MULTIDRUG RESISTANCE PROTEIN 1; RESTRICTION ENDONUCLEASE;

ADOLESCENT; ADULT; AGAR GEL ELECTROPHORESIS; ARTICLE; BRAZIL; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; EUROPEAN AMERICAN; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; PLEURISY; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; RASH; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 54349105231     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2008000900005     Document Type: Article

References (20)

1. Schiengold M, Schwantes L, Schwartsmann G, Chies JA, Nardi NB. Multidrug resistance gene expression during the murine ontogeny. Mech Ageing Dev 2001; 122: 255-270.
2. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75: 13-33.
3. Wang D, Sadee W. Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1). AAPS J 2006; 8: E515-E520.
4. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002; 71: 297-303.
5. Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002; 72: 572-583.
6. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz Ul, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189-199.
7. Diaz-Borjon A, Richaud-Patin Y, Alvarado de la Barrera C, Jakez-Ocampo J, Ruiz-Arguelles A, Llorente L. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part II: Increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control. Joint Bone Spine 2000; 67: 40-48.
8. Tsujimura S, Saito K, Nakayamada S, Tanaka Y. Relevance of multidrug resistance 1 and P-glycoprotein to drug resistance in patients with systemic lupus erythematosus. Histol Histopathol 2007; 22: 465-468.
9. Vasoo S, Hughes GR. Theory, targets and therapy in systemic lupus erythematosus. Lupus 2005; 14: 181-188.
10. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169-174.
11. Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2002; 2: 191-196.
12. Abramson JH. WINPEPI (PEPI-for-Windows) computer programs for epidemiologists. Epidemiol Perspect Innov 2004; 1: 6.
13. Lenth R. Java applets for power and sample size. [Computer program]. http://www.stat.uiowa.edu/~rienth/. 2006.
14. Furuno T, Landi MT, Ceroni M, Caporaso N, Bernucci I, Nappi G, et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 2002; 12: 529-534.
15. Bernal ML, Sinues B, Fanlo A, Mayayo E. Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther Drug Monit 2003; 25: 107-111.
16. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11: 217-221.
17. Pawlik A, Wrzesniewska J, Fiedorowicz-Fabrycy I, Gawronska-Szkiarz B. The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 2004; 42: 496-503.
18. Park SW, Lomri N, Simeoni LA, Fruehauf JP, Mechetner E. Analysis of P-glycoprotein-mediated membrane transport in human peripheral blood lymphocytes using the UIC2 shift assay. Cytometry A 2003; 53: 67-78.
19. Llorente L, Richaud-Patin Y, Diaz-Borjon A, Alvarado de la Barrera C, Jakez-Ocampo J, De La Fuente H, et al. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part I: Increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine 2000; 67: 30-39.
20. Ruiz-Soto R, Richaud-Patin Y, Lopez-Karpovitch X, Llorente L. Multidrug resistance-1 (MDR-1) in autoimmune disorders III: increased P-glycoprotein activity in lymphocytes from immune thrombocytopenic purpura patients. Exp Hematol 2003; 31: 483-487.